Sonidegib

Drug Profile

Sonidegib

Alternative Names: Erismodegib; LDE-225; NVP-LDE-225; Odomzo

Latest Information Update: 29 Dec 2016

Price : $50

At a glance

  • Originator Novartis
  • Developer Groupe Francophone des Myelodysplasies; Massachusetts General Hospital; Mayo Clinic; National Cancer Institute (USA); Novartis; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Stanford University; University of Alabama at Birmingham
  • Class Antineoplastics; Biphenyl compounds; Morpholines; Phenyl ethers; Pyridines; Small molecules
  • Mechanism of Action SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Basal cell cancer
  • Phase II Haematological malignancies; Medulloblastoma; Multiple myeloma; Solid tumours
  • Phase I/II Myelofibrosis; Ovarian cancer; Pancreatic cancer
  • Phase I Breast cancer; Chronic myeloid leukaemia; Graft-versus-host disease; Hepatocellular carcinoma; Myelodysplastic syndromes; Oesophageal cancer; Prostate cancer
  • Discontinued Basal cell nevus syndrome

Most Recent Events

  • 22 Dec 2016 Sun Pharma plans to acquire Sonidegib (Odomzo®) worldwide
  • 17 Nov 2016 Stanford University completes a clinical trial in Basal cell cancer (Second-line therapy or greater, Metastatic disease) in USA (PO) (NCT01529450)
  • 05 Oct 2016 Efficacy, adverse events and pharmacokinetics data from a phase I trial in Breast cancer presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top